1.
2.
First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults
by Luabeya, Angelique Kany Kany
Vaccine, 2015, Vol.33 (33), p.4130-4140
3.
Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting
by Penn-Nicholson, Adam
Vaccine, 2015, Vol.33 (32), p.4025-4034
4.
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial
by Geldenhuys, Hennie
Vaccine, 2015, Vol.33 (30), p.3592-3599
5.
6.
A controlled trial of sputum induction and routine collection methods for TB diagnosis in a South African community
by Geldenhuys, H. D
European journal of clinical microbiology & infectious diseases, 2014-07-15, Vol.33 (12), p.2259-2266
7.
The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses
by Kagina, Benjamin M.N
Vaccine, 2014, Vol.32 (45), p.5908-5917
8.
Phenotypic variability in childhood TB: Implications for diagnostic endpoints in tuberculosis vaccine trials
by Mulenga, Humphrey
Vaccine, 2011, Vol.29 (26), p.4316-4321
9.
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
by Tameris, Michele D, Dr
The Lancet (British edition), 2013, Vol.381 (9871), p.1021-1028
10.
Safety and immunogenicity of candidate vaccine M72/AS01Ein adolescents in a TB endemic setting
by Adam Penn-Nicholson
Vaccine, 2015-07-31, Vol.33 (32), p.4025
11.
